The NCPE do not consider ruxolitinib to be a cost effective treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.
The NCPE conclude that apixaban can be considered cost effective for the prevention of stroke and systemic embolism in people with non valvular atrial fibrillation.
The NCPE believe that Omacor® is not a cost-effective adjuvant treatment for patients post-myocardial infarction in the Irish Healthcare Setting. The cost effectiveness of Omacor® for treatment of endogenous hypertriglyceridaemia as a supplement to diet has not been demonstrated.
The NCPE believe that, at the submitted price, pirfenidone is not cost-effective for the treatment of patients with mild to moderate Idiopathic Pulmonary Fibrosis.
Fidaxomicin (Dificlir®) may be considered a cost-effective use of resources. It should be prescribed according to the recommendations outlined in the recently updated National Clostridium difficile Guidelines (due to be completed in February 2013 www.hpsc.ie).
The NCPE recommendation on ivacaftor (Kalydeco®), led to follow-up discussions between the HSE CPU and the company, Vertex Pharmaceuticals, resulting in a positive recommendation on the provision of the drug for Irish CF patients, whilst at the same time significantly reducing the budget impact of the drug.
The NCPE recommends reimbursement of bendamustine (Levact®) for patients unable to tolerate fludarabine/clyclophosphamide.
The NCPE believe that, at the submitted price, eribulin (Halaven®) is not cost effective for the treatment of patients with locally advanced breast cancer or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease.
For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. The NCPE believe that, at the submitted price, vemurafenib (Zelboraf®) is not cost effective for this indication.
As the manufacturer is unable to demonstrate the cost-effectiveness of fampridine we are unable to recommend reimbursement